Indegene Ltd

Indegene Dividend

Indegene Limited fixed July 31, 2026, as the record date for its ₹2.25 per share final dividend. The 28th AGM is scheduled for August 13, 2026.

Indegene Board Meeting Date

Indegene Ltd announces a board meeting on 30 July 2026 to approve unaudited Q2 results and ESOP/RSU allotments. Trading window will resume after results release.

Indegene Other Announcement

Indegene Limited disclosed under SEBI takeover regulations that it has no identifiable promoter for FY2025-26. Investors are informed of the company's promoter-less status.

Indegene Employee Stock Options

Indegene Limited allotted 52,951 equity shares following the exercise of employee stock options. This marginally increases the paid-up capital to ₹48.19 Crore.

Value

₹0.11 Cr

Indegene Earnings Call: Key Takeaways

Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.

Indegene Earnings Call: Key Takeaways

Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.

Indegene Earnings Call: Key Takeaways

Indegene crossed ₹1,000Cr quarterly revenue milestone in Q4FY26. Strategy focuses on GenAI-led transformation (Tectonic model) and deepening top-20 global pharma relationships.

Indegene Legal & Regulatory

Indegene Ltd received a ₹43.69 Crore income tax demand notice for Assessment Year 2023-24. The demand arises from transfer pricing adjustments. The company is pursuing resolution through the Mutual Agreement Procedure (MAP) and domestic appellate remedies, and does not expect a material adverse impact on its financial position.

Value

₹43.69 Cr

Indegene Other Announcement

Indegene Limited has been identified as a 'Leader' by Information Services Group (ISG) for Life Sciences Digital Services in Commercial Operations. The recognition highlights Indegene's domain expertise and proprietary AI-led technology platforms. This marks the third consecutive year the company has achieved this leadership ranking, reinforcing its position as a trusted partner in life sciences.

Indegene Earnings Call: Key Takeaways

Indegene crossed the ₹1000cr quarterly revenue milestone for the first time in Q4FY26, though PAT was slightly dragged by exceptional legal provisions.

Indegene Fund Raise of ₹760 Cr

Indegene Limited submitted its Monitoring Agency Report for the quarter ended March 31, 2026, regarding its ₹760 Crore IPO proceeds. The report, issued by CareEdge Ratings, confirms the utilization status towards stated objects, including debt repayment and capital expenditure. The monitoring agency noted some delays in fund deployment and reallocations approved via special resolutions.

Value

₹760.0 Cr

Indegene Debt & Borrowing

Indegene Limited confirmed its status as a non-Large Corporate for the financial year 2026-27. The company reported zero outstanding borrowings as of March 31, 2026, exempting it from mandatory incremental borrowing through debt securities under SEBI's large corporate framework.

Indegene Dividend

Indegene Limited recommended a final dividend of 112.5 per equity share for the period ended April 29, 2026. The record date and general meeting date for shareholder approval will be communicated later. This announcement follows the board meeting concluded on April 29, 2026.

Indegene Earnings Call: Key Takeaways

Indegene delivered strong FY26 revenue of INR 35,105M (+23.6% YoY) with steady 19.4% EBITDA margins, driven by GenAI-led transformation in life sciences.

Indegene Results Update

Indegene Ltd reported a landmark FY26 with annual revenue reaching ₹3,510.5 Crore, up 23.6% YoY. Q4 revenue crossed the ₹1,000 Crore milestone at ₹1,003.4 Crore with 32.8% growth. The Board recommended a final dividend of ₹2.25 per share. Management highlighted strong strategic depth with 53 clients contributing over $1M annually.

Value

₹3,510 Cr

Indegene Q4 FY26 Results: Net Profit ₹79.7 Cr, Down 32.2% YoY

Indegene Ltd reported revenue from operations of ₹1,003 Cr (+32.8% YoY) and net profit of ₹79.7 Cr (-32.2% YoY) for Q4 FY26.

Key figure

Net profit ₹79.7 Cr · -32.2% YoY

Indegene Financial Results

Indegene Limited reported audited FY26 consolidated revenue of ₹3,510.5 Crore and a net profit of ₹401.1 Crore. The Board recommended a final dividend of ₹2.25 per equity share, involving an outflow of ₹54.2 Crore. The company also approved policy amendments and ESOP allotments following its successful IPO during the year.

Value

₹54.20 Cr

Indegene Board Meeting Outcome

Indegene Limited has scheduled a board meeting for April 29, 2026, to consider audited standalone and consolidated financial results for the year ended March 2026. The board will also evaluate a recommendation for a final dividend. Trading window closure remains in effect until May 1, 2026.

Indegene Board Meeting Outcome

Indegene Limited's Board of Directors will meet on April 29, 2026, to approve audited financial results for the year ended March 31, 2026. The Board will also consider recommending a final dividend and approving ESOP allotments. Consequently, the trading window is closed until 48 hours after the results declaration.

Indegene Q3 FY26 Results: Net Profit ₹103 Cr, Down 6.4% YoY

Indegene Ltd reported net profit of ₹103 Cr (-6.4% YoY) for Q3 FY26.

Key figure

Net profit ₹103 Cr · -6.4% YoY